The report provides comprehensive information on the
therapeutics under development for Chronic
Cough, complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
report also covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key players involved
in therapeutic development for Chronic Cough and features dormant and
discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/711827-chronic-cough-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape of Chronic Cough
- The report reviews pipeline therapeutics for Chronic Cough
by companies and universities/research institutes based on information derived
from company and industry-specific sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Cough
therapeutics and enlists all their major and minor projects
- The report assesses Chronic Cough therapeutics based on
drug target, mechanism of action (MoA), route of administration (RoA) and
molecule type
- The report summarizes all the dormant and discontinued pipeline
projects
- The report reviews latest news related to pipeline
therapeutics for Chronic Cough
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Chronic Cough
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Chronic Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from
pipeline
Table of
Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Chronic Cough Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Cough - Overview 8
Pipeline Products for Chronic Cough - Comparative Analysis 9
Chronic Cough - Therapeutics under Development by Companies
10
Chronic Cough - Therapeutics under Investigation by
Universities/Institutes 11
Chronic Cough - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Chronic Cough - Products under Development by Companies 14
Chronic Cough - Products under Investigation by
Universities/Institutes 15
Chronic Cough - Companies Involved in Therapeutics
Development 16
Afferent Pharmaceuticals, Inc. 16
AstraZeneca Plc 17
Conrig Pharma ApS 18
GlaxoSmithKline Plc 19
Glenmark Pharmaceuticals Ltd. 20
GW Pharmaceuticals Plc 21
NeRRe Therapeutics Ltd 22
Patara Pharma, Inc. 23
Pila Pharma AB 24
Chronic Cough - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 33
AF-219 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
cromolyn sodium - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
GRC-17536 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GSK-2339345 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
lesogaberan - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
NEO-5937 - Drug Profile 42
Product Description 42
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
No comments:
Post a Comment